Alzheimer's Disease and Memory Disorders Center
Click on the sign to list the poster and platform presentations by year. Then click on the link to view that presentation.
2023
- Early-life social determinants of SCA6 age at onset, severity, and progression.
- Gambling associated risk-taking decision in cerebellar ataxia.
- Cognitive function remains associated with global functional impairment in profound dementia due to Alzheimer's disease and dementia with Lewy bodies.
- Precision neurology for dementia.
American Academy of Neurology (AAN)
75th Annual Meeting in Boston, Mass. (April 22-28, 2023)
2022
2021
- The implication of pyramidal signs in multiple system atrophy.
[Previously Presented]
- Distinct impulsive traits in cerebellar ataxia and Parkinson's disease.
- The implication of pyramidal signs in multiple system atrophy.
- U.S. POINTER: Lessons learned about delivery of a multi-domain lifestyle intervention during the COVID-19 pandemic.
- The implication of upper motor neuron burden in multiple system atrophy.
- Cerebellar Impulsivity-Compulsivity Assessment (CIA): A scale to measure impulsive and compulsive behaviors in cerebellar disorders.
- Corticobasal degeneration and auditory hallucination.
American Neurological Association (ANA)
146th Annual Virtual Meeting (Oct. 14-19, 2021)
Movement Disorder Society (MDS)
Virtual International Congress of Parkinson's Disease and Movement Disorders. (Sept. 17-22, 2021)
2021 Alzheimer's Association International Conference (AAIC)
Virtual Meeting (July 26-30, 2021)
American Academy of Neurology (AAN)
Virtual 2021 Annual Meeting (April 17-22, 2021)
<2020
- Impulsivity in cerebellar ataxias: Testing the cerebellar reward hypothesis in humans.
[Previously Presented]
- US-POINTER (USA).
[Platform Presentation]
- Different profiles of cognitive deficits predict progression rate in probable AD.
- Impulsivity in cerebellar ataxias: Testing the cerebellar reward hypothesis in humans.
- Cholinesterase inhibitors have a disease modifying effect in AD relative to CHRFAM7A genotype suggesting an a7NAChR dependent mechanism.
- Consistently large amyloid reductions in patients with and without ARIA-E in the gantenerumab SCarlet RoAD and Marguerite RoAD open-label extension studies.
[Platform Presentation]
- Baseline characteristics from a phase III trial of crenezumab in early (prodromal-to-mild) Alzheimer's disease (CREAD).
- Temporal trends in mortality in an AD clinical cohort.
- Update on the safety and tolerability of gantenerumab in the ongoing open-label extension (OLE) of the Marguerite Road Study in patients with mild Alzheimer's disease (AD) after approximately two years of study duration.
- Update on the safety and tolerability of gantenerumab in the ongoing open-label extension of the Scarlet Road Study in patients with prodromal Alzheimer's disease after approximately two years of study duration.
- Concord-AD: An international network of cohorts for better understanding of Alzheimer's disease.
- Twenty-four month amyloid PET results of the gantenerumab high dose open label extension studies.
- Baseline characteristics from a phase 3 trial of crenezumab in prodromal to mild Alzheimer's disease (CREAD).
- Twenty year trends in proportional mortality in a probable AD cohort.
- The effect of low doses of gantenerumab on amyloid and tau biomarkers in cerebrospinal fluid (CSF) in the Marguerite Road Study.
- Serum anti-gliadin antibodies in cerebellar ataxias: A systematic review and meta-analysis.
[Previously Presented]
- Higher dose gantenerumab leads to significant reduction in amyloid plaque burden - Results for the Marguerite and Scarlet Road open label extension studies.
- Serum anti-gliadin antibodies in cerebellar ataxias: A systematic review and meta-analysis.
- Wernicke encephalopathy masquerading as a right middle cerebral artery territory infarction.
- Validation of a pre-diagnostic progression rate used to predict post-diagnostic change on common Alzheimer's disease outcome measures.
- Predictors of atypical antipsychotic treatment in an AD clinical population.
- Cohort effects in progression rate in a clinical registry of Alzheimer's patients accrued from 1995-2010.
- Longitudinal cognitive asymmetry and decline in Alzheimer's disease patients.
- Advancing therapeutics for neuroinflammation in Alzheimer's disease: Clinical development considerations.
- PRISM II: Effectiveness of dextromethorphan 20 mg/quinidine 10 mg (Nuedexta®) for treatment of pseudobulbar affect secondary to dementia, stroke, or traumatic brain injury: Combined results of a multicenter open-label study.
- Randomized, double-blind, placebo-controlled studies to evaluate treatment with aducanumab (BIIB037) in patients with early Alzheimer's disease: Phase 3 study design.
[Oral Presentation]
- Validation of olfactory identification deficit as a biomarker of Alzheimer's disease.
- Dextromethorphan/quinidine for treatment of pseudobulbar affect (PBA) in patients with dementia: Comparison of patient-reported ratings to those of caregiver proxies in a 12-week open-label trial (PRISM II).
- Dextromethorphan/quinidine for treatment of pseudobulbar affect (PBA) in patients with dementia: Examination of CNS-LS outcomes in a 12-week open-label trial (PRISM II).
- Dextromethorphan/quinidine for treatment of pseudobulbar affect in patients with dementia: Treatment effects by concomitant antidepressant use in a 12-week open-label trial (PRISM II).
[Platform Presentation]
- TTP488 path to registration: Leveraging enrichment strategies.
- TTP488: From futile to fast track.
- Selection of resources from a vaccination standing order program toolkit during a randomized trial to improve vaccination rates in a PBRN.
- Content of patient instructions section of an EHR generated after visit summary affects patient satisfaction.
- Validation of olfactory deficit as a biomarker of Alzheimer's disease.
- PRISM II: An open-label study to assess the safety, tolerability, and effectiveness of dextromethorphan 20 mg/quinidine 10 mg for treatment of pseudobulbar affect secondary to dementia, stroke, or traumatic brain injury: Results from the Alzheimer's disease/dementia cohort.
- Provider survey of attitudes toward and uses of an electronic after visit summary.
- Patterns of glycemic control with exclusive oral hypoglycemic agent use in a community health care setting.
- WIP safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with Alzheimer's disease/dementia: PRISM-II.
- Antioxidant biomarkers predict annualized change in MMSE score in MCI and AD patients in the TARCC cohort.
- Comparing recruitment among geographic regions in multinational Alzheimer's disease clinical trials.
- Regional variation in Alzheimer's disease progression in a clinical trial setting.
- Development of a codebook to describe the content of the patient instructions section of an EHR-generated after visit summary.
- Progression and stability of cognitive asymmetry in a large sample of Alzheimer's disease patients.
- A study to assess the safety, tolerability, and effectiveness of Nuedexta (dextromethorphan 20 mg/quinidine 10 mg) in the treatment of pseudobulbar affect (PBA) [PRISM II].
- Ordered subset analysis CNV association with Alzheimer's disease AAO phenotypes.
- A simple method for enhancing prediction of longitudinal decline in instrumental activities of daily living in Alzheimer's patients.
- Improving predictive validity of the Clinical Dementia Rating Scale for functional outcomes.
- Mexican American normative references on tasks of memory and language: The Texas Mexican American normative studies.
- Normative data for Mexican American on tasks of executive and physiometric functions: The Texas Mexican American normative studies.
- Normative performance on the RBANS in a multi-ethnic bilingual cohort: The Texas Mexican American normative studies.
- Genome-wide scan for copy number variation association with age at onset of Alzheimer's disease.
[Platform Presentation]
- Premorbid IQ and intrinsic progression rate explain substantial variance in observed progression of Alzheimer's disease (AD) on multiple measures.
- Factors influencing time to nursing home placement in persons with probable Alzheimer's disease.
- Factors that influence long term care placement in an Alzheimer disease cohort.
- Integrated copy number and gene expression analysis detects a CREB1 association with Alzheimer's disease.
- Dimebon in Alzheimer's disease: Summary and contract of three efficacy trials.
- Pooled analysis of three cluster randomized hypertension control trials in African-Americans.
- Plasma cortisol does not predict rate of cognitive decline in Alzheimer's patients.
- Amnestic MCI, sleep disturbance, and cognitive functioning.
- Serum granulocyte colony stimulating factor and Alzheimer's disease.
- The impact of depression on cognition varies by APOE4 status.
- Biomarkers associated with cardiovascular risk in the Texas Alzheimer's Disease Research and Care Consortium (TARCC) Cohort: LpPla2 and homocysteine.
- Inflammatory biomarkers in the Texas Alzheimer's Research and Care Consortium (TARCC) Cohort.
- Plasma sphingomyelin is associated with cognitive progression in Alzheimer's disease.
- Refinement and expansion of the Texas Alzheimer's research consortium serum-based diagnostic algorithm for Alzheimer's disease.
- A serum protein-based algorithm for the detection of Alzheimer's disease.
- Racial/ethnic group differences in the association of APOE ε4 genotype and visuospatial test performance in a non-demented sample.
- Factors that influence survival in Alzheimer's patients.
- The cognitive correlates of functional status: a new approach to dementia.
- Genome-wide association scan replication for biomarker endophenotypes of Alzheimer's disease.
- Developing and validating of diagnostic algorithm for Alzheimer's disease.
- Efficacy and safety of donepezil 23 mg/day in patients with moderate-to-severe Alzheimer's disease with concomitant memantine use.
- Differences in the association of peripheral insulin and cognitive function in non-diabetic ad cases and normal controls.
- Differential recall of nouns and verbs in patients with probable Alzheimer's disease (AD).
- Cognitive reserve as a moderator for the relationship between depression and cognitive functioning in Alzheimer's disease.
- Cortisol levels in Alzheimer's patients are related to premorbid functioning and rate of progression.
- An inflammatory endophenotype of Alzheimer's disease.
- Presence of cardiovascular disease is associated with slower cognitive decline in Alzheimer's disease in the absence of cerebrovascular pathology.
- A serum protein-based diagnostic algorithm for Alzheimer's disease.
- Results from CONNECTION: A global, Phase 3 double-blind, placebo-controlled confirmatory trial of dimebon (latrepirdine) in patients with mild-to-moderate Alzheimer's disease.
- Association of genetic variation in the electron transport chain and Alzheimer's disease.
- Genome-wide association scan for biomarker endophenotypes of Alzheimer's disease.
- How well does the ADAS-cog measure the spectrum of Alzheimer's disease severity? An item response theory analysis.
- Age at onset and pre- morbid IQ influence early progression rates in AD.
- Systematic bias in blood pressure measurement between health care systems - Implications for quality of care research.
- Eighteen-month data from an open-label extension of a one-year controlled trial of dimebon in patients with mild-to-moderate Alzheimer's disease.
- Interrater reliability between expert and nonexpert physicians in the assessment of amnestic MCI in the community setting.
- Dimebon improves cognition, function, and behavior in mild and moderate Alzheimer's disease: Results by severity of a one-year, double-blind, placebo-controlled study.
- The effects of donepezil on Alzheimer's disease progression monitored by MRI.
- Persistent antidementia drug treatment and survival in an Alzheimer's disease (AD) cohort.
- The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Effect of atorvastatin on Alzheimer's disease progression by APOE4 genotype.
- Inter-rater reliability between expert and nonexpert physicians in the diagnosis of amnestic MCI in the community setting.
- Dimebon improves patient function and decreases caregiver assistance time in Alzheimer's disease: One-year clinical trial results.
- Dimebon improves memory, orientation, language, and praxis in patients with mild to moderate Alzheimer's disease: Results of a one-year placebo-controlled study.
- Vitamin E use is associated with improved survival in an AD cohort.
- Results of a one-year randomized, placebo-controlled trial of dimebon for the treatment of mild to moderate Alzheimer's disease.
- Lipitor's effect in Alzheimer's dementia (LEADe) study: Baseline characteristics.
- Clinical factors associated with the preprogression rate (PPR) in Alzheimer's disease (AD).
- The dementia and disability in Thai elderly project: Prevalence of mild cognitive impairment with one-year follow-up and the prevalence of dementia in community-dwelling Thai elderly.
- Dimebon improves cognition, function, and behavior in patients with mild- moderate Alzheimer's disease: Results of a randomized, double-blind, placebo-controlled study.
- Design and baseline data for a study of Lipitor's effect in Alzheimer's disease (LEADe).
- Agreement between stage of change and measured behavioral endpoints: Implications for intervention design.
- Association between serum c-peptide levels and the risk of cardiovascular disease in nondiabetic individuals: Data from the National Health and Nutrition Examination Survey.
- Predicting progression and survival in Alzheimer's disease.
- Is functional decline necessary for a diagnosis of Alzheimer's disease?
- Clinically presenting mild cognitive impairment (MCI): Variable presentations and their outcomes.
- Preprogression rate, cardiovascular comorbidity, and survival in Alzheimer's disease.
- Association between cognitive function and metabolic control parameters in treated patients with type 2 diabetes.
- Neuropsychological and demographic correlates of apraxia in a large cohort of Alzheimer's patients.
- Phonemic cued performance on the Boston Naming Test: Longitudinal change and its correlates in Alzheimer's disease.
- Naming improvement with phonemic cues: Which Alzheimer's patients benefit most?
- Category-letter fluency discrepancies in healthy older adults: Normative data and reliability.
- Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease.
- Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease.
- Donepezil and vitamin E in the progression of mild cognitive impairment to Alzheimer's disease: A hazard-ratio analysis.
- Mild cognitive impairment types and their outcomes.
- ADAS-Cog change rates in MMSE Strata relevant to clinical trials.
- Relationship of premorbid IQ and education to progression of Alzheimer's disease.
- Donepezil is safe and well-tolerated in AD patients at doses of up to 20 mg/day.
- Functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease.
- Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits.
- Longitudinal analysis of the Alzheimer's Disease assessment scale in a large cohort of probable AD patients.
- Memantine treatment for mild to severe Alzheimer's disease: Clinical trials summary.
- Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease.
- Memantine treatment is beneficial for functional capacities of patients with moderate to severe Alzheimer's disease.
- Donepezil-treated patients demonstrate global benefits on the Clinician's Interview-Based Impression of Change-Plus version: A comparison of Alzheimer's disease versus vascular dementia.
- Long-term treatment with the NMDA antagonist, memantine: Results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease.
- How well do cerebral spinal fluid tau levels discriminate autopsy confirmed Alzheimer's disease from other dementia diagnoses?
- Pathogenesis and treatment strategies for selected therapies under development.
- Long term treatment with the NMDA antagonist memantine: results of a 24-week, open label extension study in moderately severe to severe Alzheimer's disease.
- Cognitive function and cardiovascular risk factors in adults 30-59 years old (NHANES III).
- Selective physician blood pressure remeasurement in the office setting may contribute to poor hypertension control.
- Survival in patients with dementia from a large multi ethnic population.
- Growth curve analysis of decline in instrumental activities of daily living in AD patients.
- Measurement invariance of the WAIS-R in AD among patients at higher versus lower levels of dementia severity.
- WAIS-R factor structure in AD: Comparison of alternative models and assessment of generalizability.
- Self-assessed knowledge of diabetes management in a low-income, minority patient population.
- Racial differences among patients with Alzheimer's disease from a large multi ethnic population.
- The cognitive benefits of galantamine are sustained for at least 24 months: Results of a long-term extension trial in Alzheimer's disease.
- Improvement in systolic blood pressure control in a predominantly African-American health center.
- Cholinesterase inhibitors: Benefits and limitations.
- Donepezil preserves activities of daily living in Alzheimer's disease patients: Results from a 1-year placebo-controlled functional survival study.
- Profoundly advanced Alzheimer's disease: Patient characteristics, functional status, disease progression, and care burden.
- Uninterrupted long-term donepezil treatment results in optimal efficacy with retained safety.
- Donepezil preserves functional status in Alzheimer's disease patients: Results from a 1-year placebo-controlled attrition study.
- Optimal donepezil efficacy in Alzheimer's disease is dependent on continued administration.
- Does ApoE4 correlate with MRI changes in Alzheimer's disease?
- Clinical benefits of donepezil: Results from a long-term phase III extension trial.
- Donepezil improves cognition and global function in Alzheimer's disease: Results from U.S. and multinational phase III clinical trials.
- Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease patients.
- The presence of APO E4 does not influence rate of decline in Alzheimer's disease.
- Ethnic differences in 24-hour blood pressure control in treated hypertensives.
- Current therapeutic standards in the treatment of Alzheimer's disease.
- Research outcome measures in Alzheimer's disease: Statistical significance, effect size and responder analysis - How do they translate to clinical relevance?
- Outcome measures in dementia trials-video CIBIC validity and reliability.
- Donepezil HCI (E2020) improves cognitive and global function in patients with mild and moderately severe Alzheimer's disease: Results of a 15-week phase III study.
- Prevalence of uncontrolled hypertension in a population of Alzheimer's patients.
- Rate of dementia of the Alzheimer's type (DAT) in subjects with mild cognitive impairment.
- E-2020 Produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease (AD): Results of a 30-week phase III trial.
- Pharmacologic evidence for autonomic sudomotor dysfunction in patients with Alzheimer's disease.
- Reliability and validity of a new clinical global rating scale for Alzheimer's clinical trials.
- A new clinical global rating scale for Alzheimer's clinical trials.
- Estrogen and psychomotor performance.
- A calculated measure to predict rate of progression in Alzheimer's disease.
- Sex differences involving naming in Alzheimer's disease: Stronger relationships with left hemisphere functioning in men.
- Psychometric profiles of Alzheimer's disease (AD) with/without white matter changes compared to subcortical ischemic vascular dementia (IVD).
- Neuropsychological distinctions between cortico-basal ganglionic degeneration (CBGD) and Alzheimer's disease with extrapyramidal signs.
- Neuropsychological differentiation of corticobasal degeneration from Alzheimer's disease.
- Dysfluency in the speech of AD patients.
- Literacy and cognition in northern Thailand.
- Simulation analysis of a large British pedigree segregating a newly characterized autosomal dominant language disorder: Familial developmental dysphasia.
- Neuroimaging findings and clinical variables associated with psychosis in Alzheimer's disease.
- Correlates of asymmetric motor speed in Alzheimer's disease.
- Neuropsychological correlates of apraxia in Alzheimer's disease patients.
- Single photon emission computerized tomography (SPECT) in Alzheimer's disease and multiple-infarct dementia.
- Establishing the limits of the mini-mental state: MMS "subtests" versus a full neuropsychological battery.
- Positive and negative psychiatric symptoms in Alzheimer's disease.
- The alien hand and related signs.
- Recurrent posterior-type aphasia associated with a seizure focus.
- Progressive nonfluent aphasia.
- Effects of stress management and dietary changes in treating ischemic heart disease.
Movement Disorder Society (MDS)
Virtual International Congress of Parkinson's Disease and Movement Disorders. (Sept. 12-16, 2020)
2020 Alzheimer's Association International Conference (AAIC)
Virtual Meeting (July 27-31, 2020)
American Academy of Neurology (AAN)
72nd Annual Meeting in Toronto, Ontario, Canada (April 25 - May 1, 2020)
2019 Alzheimer's Association International Conference (AAIC)
Los Angeles, Calif. (July 14-18, 2019)
American Academy of Neurology (AAN)
71st Annual Meeting in Philadelphia, Penn. (May 4-10, 2019)
14th International Conference on Alzheimer's and Parkinson's Diseases (ADPD)
Lisbon, Portugal (March 26-31, 2019)
2018 Alzheimer's Association International Conference (AAIC)
Chicago, Ill. (July 22-26, 2018)
Columbia University College of Physicians and Surgeons
1st International Tremor Congress in New York City, N.Y. (May 11-12, 2018)
American Academy of Neurology (AAN)
70th Annual Meeting in Los Angeles, Calif. (April 21-27, 2018)
2017 Alzheimer's Association International Conference (AAIC)
London, United Kingdom (July 15-20, 2017)
International Neuropsychological Society (INS)
45th Annual Meeting in New Orleans, La. (Feb. 1-7, 2017)
2016 Alzheimer's Association International Conference (AAIC)
Toronto, Canada (July 22-28, 2016)
American Academy of Neurology (AAN)
68th Annual Meeting in Vancouver, BC, Canada (April 15-21, 2016)
Society for Neuroscience (SFN)
45th Annual Meeting in Chicago, Ill. (Oct. 17-21, 2015)
2015 Alzheimer's Association International Conference (AAIC)
Washington, DC (July 18-23, 2015)
North American Primary Care Research Group (NAPCRG)
2015 Practice-Based Research Network Conference in Bethesda, Md. (June 29-30, 2015)
American Academy of Neurology (AAN)
67th Annual Meeting in Washington, DC (April 18-25, 2015)
North American Primary Care Research Group (NAPCRG)
42nd Annual Meeting in New York, N.Y. (Nov. 21-25, 2014)
American Neurological Association (ANA)
139th Annual Meeting in Baltimore, Md. (Oct. 12-14, 2014)
2014 Alzheimer's Association International Conference (AAIC)
Copenhagen, Denmark (July 12-17, 2014)
North American Primary Care Research Group (NAPCRG)
2014 Practice-Based Research Network Conference in Bethesda, Md. (June 30 - July 1, 2014)
International Neuropsychological Society (INS)
42nd Annual Meeting in Seattle, Wash. (Feb. 12-15, 2014)
2013 Alzheimer's Association International Conference (AAIC)
Boston, Mass. (July 13-18, 2013)
American Academy of Neurology (AAN)
65th Annual Meeting in San Diego, Calif. (March 16-23, 2013)
International Neuropsychological Society (INS)
41st Annual Meeting in Montreal, Waikoloa, Hawaii (Feb. 6-9, 2013)
National Academy of Neuropsychology (NAN)
32nd Annual Meeting in Nashville, Tenn. (Nov. 7-10, 2012)
American Neurological Association (ANA)
137th Annual Meeting in Boston, Mass. (Oct. 7-9, 2012)
Alzheimer's Association International Conference (AAIC)
Annual Meeting in Vancouver, British Columbia, Canada (July 14-19, 2012)
American Society of Hypertension (ASH)
27th Annual Scientific Meeting and Exposition in New York, N.Y. (May 19-22, 2012)
International Neuropsychological Society (INS)
40th Annual Meeting in Montreal, Quebec, Canada (Feb. 15-18, 2012)
2011 International Conference on Alzheimer's Disease (ICAD)
Paris, France (July 16-21, 2011)
American Academy of Neurology (AAN)
63rd Annual Meeting in Honolulu, Hawaii (April 9-16, 2011)
International Neuropsychological Society (INS)
39th Annual Meeting in Boston, Mass. (Feb. 2-5, 2011)
2010 International Conference on Alzheimer's Disease (ICAD)
Honolulu, Hawaii (July 10-15, 2010)
American Academy of Neurology (AAN)
61st Annual Meeting in Seattle, Wash. (April 25 - May 2, 2009)
American Heart Association
Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference in Washington, DC (April 23-25, 2009)
International Neuropsychological Society (INS)
37th Annual Meeting in Atlanta, Ga. (Feb. 11-14, 2009)
2008 International Conference on Alzheimer's Disease (ICAD)
Chicago, Ill. (July 26-31, 2008)
American Academy of Neurology (AAN)
60th Annual Meeting in Chicago, Ill. (April 12-19, 2008)
American Neurological Association (ANA)
132nd Annual Meeting in Washington, DC (Oct. 7-10, 2007)
2nd International Frontotemporal Dementia in ALS Research Conference
London, Ontario Canada (June 10-13, 2007)
Alzheimer's Association International Conference (AAIC)
Washington, DC (June 9-12, 2007)
American Academy of Neurology (AAN)
59th Annual Meeting in Boston, Mass. (April 28 - May 5, 2007)
8th International Conference on Alzheimer's and Parkinson's Diseases (ADPD)
Salzburg, Austria (March 14-18, 2007)
American Heart Association
47th Annual Conference on Cardiovascular Disease Epidemiology and Prevention in Orlando, Fla. (Feb. 28 - March 3, 2007)
10th International Conference on Alzheimer's Disease and Related Disorders
Madrid, Spain (July 15-20, 2006)
American Academy of Neurology (AAN)
58th Annual Meeting in San Diego, Calif. (April 1-8, 2006)
American Heart Association/National Heart, Lung, and Blood Institute
46th Annual Conference on Cardiovascular Disease Epidemiology and Prevention in Phoenix, Ariz. (March 2-5, 2006)
International Neuropsychological Society (INS)
34th Annual Meeting in Boston, Mass. (Feb. 1-4, 2006)
American Neurological Association (ANA)
130th Annual Meeting in San Diego, Calif. (Sept. 25-28, 2005)
2nd Alzheimer's Association International Conference (AAIC)
Washington, DC (June 9-12, 2005)
American Academy of Neurology (AAN)
57th Annual Meeting in Miami Beach, Fla. (April 9-16, 2005)
European Federation of Neurological Societies (EFNS)
8th Congress in Paris, France (Sept. 4-7, 2004)
9th International Conference on Alzheimer's Disease and Related Disorders
Philadelphia, Penn. (July 17-22, 2004)
XXIVth Collegium Internationale Neuro-Psychopharmacologicum (CINP) Congress
Paris, France (June 20-24, 2004)
American Academy of Neurology (AAN)
55th Annual Meeting in Honolulu, Hawaii (March 29 - April 5, 2003)
8th International Conference on Alzheimer's Disease and Related Disorders
Stockholm, Sweden (July 20-25, 2002)
Society for Epidemiologic Research (SER)
35th Annual Meeting in Palm Desert, Calif. (June 19-21, 2002)
American Society of Hypertension (ASH)
17th Annual Meeting in New York, N.Y. (May 14-18, 2002)
World Federation of Neurology (WFN)
Research Group on Neuroepidemiology. Regional North American Annual Meeting in Denver, Colo. (April 19, 2002)
International Neuropsychological Society (INS)
30th Annual Meeting in Toronto, Canada (Feb. 13-16, 2002)
North American Primary Care Research Group (NAPCRG)
29th Annual Meeting in Halifax, Nova Scotia, Canada (Oct. 13-16, 2001)
World Federation of Neurology (WFN)
Research Group on Neuroepidemiology. Regional North American Annual Meeting in Philadelphia, Penn. (May 9, 2001)
American Academy of Neurology (AAN)
53rd Annual Meeting in Philadelphia, Penn. (May 5-11, 2001)
North American Primary Care Research Group (NAPCRG)
28th Annual Meeting in Amelia Island, Fla. (Nov. 4-7, 2000)
7th International Conference on Alzheimer's Disease and Related Disorders
Washington, DC (July 9-18, 2000)
American Academy of Neurology (AAN)
52nd Annual Meeting in San Diego, Calif. (April 29 - May 6, 2000)
American Society of Consultant Pharmacists (ASCP)
30th Annual Meeting in St. Loius, Mo. (Nov. 10-13, 1999)
European College of Neuropsychopharmacology (ECNP)
12th Congress in London, United Kingdom (Sept. 21-25, 1999)
European Neurological Society (ENS)
9th Annual Meeting in Milan, Italy (June 5-9, 1999)
American Academy of Neurology (AAN)
51st Annual Meeting in Toronto, Canada (April 17-24, 1999)
European College of Neuropsychopharmacology (ECNP)
11th Congress in Paris, France (Oct. 31 - Nov. 4, 1998)
6th International Conference on Alzheimer's Disease and Related Disorders
Amsterdam, The Netherlands (July 18-23, 1998)
American Society of Hypertension (ASH)
13th Annual Meeting in New York, N.Y. (May 13-16, 1998)
5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy
Geneva, Switzerland (April 15-18, 1998)
American Academy of Neurology (AAN)
49th Annual Meeting in Boston, Mass. (April 15-17, 1997)
American College of Neuropsychopharmacology (ACNP)
35th Annual Meeting in San Juan, Puerto Rico (Dec. 9-13, 1996)
International Behavioral Neuroscience Society (ISBN)
5th Annual Meeting in Cancun, Mexico (May 2-5, 1996)
American Academy of Neurology (AAN)
48th Annual Meeting in San Francisco, Calif. (March 23-30, 1996)
International Neuropsychological Society (INS)
24th Annual Meeting in Chicago, Ill. (Feb. 14-17, 1996)
Gerontological Society of America (GSA)
50th Annual Meeting in Los Angeles, Calif. (Nov. 15-19, 1995)
American Neuropsychiatric Association (ANPA)
7th Annual Meeting in Pittsburgh, Penn. (Oct. 12-15, 1995)
American Academy of Neurology (AAN)
47th Annual Meeting in Seattle, Wash. (May 6-13, 1995)
International Neuropsychological Society (INS)
23rd Annual Meeting in Seattle, Wash. (Feb. 8-11, 1995)
American Academy of Neurology (AAN)
46th Annual Meeting in Washington, DC (May 1-7, 1994)
International Neuropsychological Society (INS)
22nd Annual Meeting in Cincinnati, Ohio (Feb. 2-5, 1994)
American Neurological Association (ANA)
118th Annual Meeting in Boston, Mass. (Oct. 18-20, 1993)
American Society of Human Genetics (ASHG)
43rd Annual Meeting in New Orleans, La. (Oct. 5-9, 1993)
American Psychiatric Association (APA)
146th Annual Meeting in San Francisco, Calif. (May 22-27, 1993)
International Neuropsychological Society (INS)
21st Annual Meeting in Galveston , Texas (Feb. 24-27, 1993)
National Academy of Neuropsychology (NAN)
12th Annual Meeting in Pittsburgh, Penn. (Nov. 5-7, 1992)
American Anthropological Association (AAA)
90th Annual Meeting in Chicago, Ill. (Nov. 20-24, 1991)
American Neurological Association (ANA)
116th Annual Meeting in Seattle, Wash. (Sept. 28 - Oct. 2, 1991)
American Academy of Neurology (AAN)
43rd Annual Meeting in Boston, Mass. (April 21-27, 1991)
American Anthropological Association (AAA)
89th Annual Meeting in New Orleans, La. (Nov. 27 - Dec. 2, 1990)
American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM)
37th Annual Meeting in Chicago, Ill. (Sept. 7-8, 1990)
American Academy of Neurology (AAN)
42nd Annual Meeting in Miami, Fla. (April 2-4, 1990)
American College of Cardiology (ACC)
31st Annual Scientific Session in Atlanta, Ga. (April 25-29, 1982)